POLICY: Hereditary Angioedema – Icatibant (Firazyr)

- Firazyr® (icatibant injection for subcutaneous use – Shire/Takeda)
- Icatibant injection for subcutaneous use – various

APPROVAL DATE: 07/24/2019

OVERVIEW
Icatibant (Firazyr, generics) is a synthetic decapeptide that is indicated for the treatment of acute hereditary angioedema (HAE) attacks in adults ≥ 18 years of age. Icatibant is a competitive bradykinin B2 receptor antagonist with an affinity similar to bradykinin. Bradykinin is a vasodilator which is likely responsible for the characteristic HAE symptoms of localized swelling, inflammation and pain. By preventing the binding of bradykinin to its receptor, icatibant treats the clinical symptoms of an acute HAE attack. HAE due to C1 esterase inhibitor (C1-INH) deficiency has two subtypes: HAE type I and HAE type II. HAE diagnosis can be confirmed by measuring functional C1-INH protein levels (usually < 50% of normal in patients with HAE), C4 levels, and C1-INH antigenic levels. Patients with HAE type I have low C4 and C1-INH antigenic protein levels, along with low levels of functional C1-INH protein. Patients with HAE type II have low C4 and functional C1-INH protein level, with a normal or elevated C1-INH antigenic protein level. C1-INH replacement therapies are appropriate for both HAE type I and type II.

Patients with the third type of HAE, previously referred to as HAE type III, have normal C4 and C1-INH antigenic protein levels. The exact cause of HAE with normal C1-INH has not been determined. There are no randomized or controlled clinical trial data available with any therapy for use in HAE with normal C1-INH. The consensus panel notes that until data from randomized controlled studies become available, no firm recommendations regarding the treatment of HAE with normal C1-INH can be made.

Guidelines
Per the World Allergy Organization (WAO)/European Academy of Allergy and Clinical Immunology (EAACI) guidelines (2017), all attacks should be considered for acute treatment; treatment is mandatory for any attack potentially affecting the upper airway. Attacks should be treated as early as possible. Self-administration at home facilitates earlier response. The guidelines recommend C1-INH products (Cinryze, Ruconest, or Berinert), Kalbitor, or icatibant as first-line treatment options. Androgens and antifibrinolytics are not effective as acute treatment. Patients should carry acute treatment with them at all times and should have enough supply on hand for treatment of two attacks. Other guidelines from the US Hereditary Angioedema Association Medical Advisory Board (2013) and a practice parameter update from a Joint Task Force (2013) have similar recommendations.

POLICY STATEMENT
Prior authorization is recommended for medical benefit coverage of icatibant. Approval is recommended for those who meet the Criteria and Dosing for the listed indication(s). Extended approvals are allowed if the patient continues to meet the Criteria and Dosing. Requests for doses outside of the established dosing documented in this policy will be considered on a case-by-case basis by a clinician (i.e., Medical Director or Pharmacist). All approvals are provided for 1 year in duration unless otherwise noted below.

Because of the specialized skills required for evaluation and diagnosis of patients with this condition, approval requires Firazyr to be prescribed by or in consultation with a physician who specializes in the condition being treated.
Documentation: Documentation will be required where noted in the criteria as [documentation required]. Documentation may include, but is not limited to, chart notes, laboratory records, and prescription claims records.

RECOMMENDED AUTHORIZATION CRITERIA
Coverage of icatibant is recommended in those who meet the following criteria:

FDA-Approved Indications

1. **Hereditary Angioedema (HAE) Due to C1 Inhibitor (C1-INH) Deficiency (Type I or Type II) – Treatment of Acute Attacks.** Approve for the duration noted if the patient meets one of the following criteria (A or B):

   A) **Initial therapy.** Approve for 1 year if the patient meets both of the following criteria (i and ii):

   i. The patient has HAE type I or type II as confirmed by the following diagnostic criteria (a and b):

   a) The patient has low levels of functional C1-INH protein (< 50% of normal) at baseline, as defined by the laboratory reference values [documentation required]; AND

   b) The patient has lower than normal serum C4 levels at baseline, as defined by the laboratory reference values [documentation required]; AND

   ii. The medication is prescribed by, or in consultation with, an allergist/immunologist or a physician that specializes in the treatment of HAE or related disorders.

   B) **Patients who have treated previous HAE attacks with icatibant (Firazyr).** Approve for 1 year if the patient meets all of the following criteria (i, ii, and iii):

   i. The patient has treated previous acute HAE type I or type II attacks with icatibant [documentation required to confirm HAE type I or type II diagnosis]; AND

   ii. According to the prescribing physician, the patient has had a favorable clinical response (e.g., decrease in the duration of HAE attacks, quick onset of symptom relief, complete resolution of symptoms, decrease in HAE acute attack frequency or severity) with icatibant treatment; AND

   iii. The medication is prescribed by or in consultation with an allergist/immunologist or a physician that specializes in the treatment of HAE or related disorders.

Dosing.¹ Approve up to 30 mg, no more frequently than three times daily.

CONDITIONS NOT RECOMMENDED FOR APPROVAL
Icatibant has not been shown to be effective, or there are limited or preliminary data or potential safety concerns that are not supportive of general approval for the following conditions. (Note: This is not an exhaustive list of Conditions Not Recommended for Approval.)

1. **Hereditary Angioedema (HAE) Prophylaxis.** Data are not available and icatibant is not indicated for prophylaxis of HAE attacks.

2. Coverage is not recommended for circumstances not listed in the Recommended Authorization Criteria. Criteria will be updated as new published data are available.

REFERENCES


### HISTORY

<table>
<thead>
<tr>
<th>Type of Revision</th>
<th>Summary of Changes</th>
<th>Approval Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>New policy</td>
<td>--</td>
<td>10/03/2018</td>
</tr>
<tr>
<td>Early annual revision</td>
<td>Generic icatibant added to policy.</td>
<td>07/24/2019</td>
</tr>
</tbody>
</table>